JMP Group Corp. (JMP) Financials Nov 10, 2014, 4:22
JMP Group Corp. (JMP) Financials Nov 10, 2014, 4:22 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for JMP Group Corp.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 180.05M 179.72M 149.05M 142.72M 180.04M
Total Investment Income 42.6M 92.98M 80.84M (300,000) 21.19M
Sundry Revenue/Income 24.86M 42.83M 21.36M 11.06M 2.6M
Trading Account Income 18.52M 3.42M 1.62M - -
Trust Income, Commissions & Fees 94.08M 40.49M 45.25M 88.66M 124.75M
Commission & Fee Income 94.08M 40.49M 45.25M 72.89M 98.8M
Total Expense 160.88M 156.26M 152.79M 133.19M 162.49M
Total Interest Expense 25.92M 33.69M 35.75M 39.99M 30.11M
Depreciation & Amortization Expense 745,571 635,000 721,000 884,000 921,000
Other Operating Expense 19.14M 23.57M 116.32M 69.59M 104.72M
2009 2010 2011 2012 2013 5-year trend
Operating Income 19.16M 23.46M (3.74M) 9.53M 17.55M
Non-Operating Income (Expense) 0 0 0 0 0
Non-Operating Interest Income - 0 0 0 0
Miscellaneous Non Operating Expense 0 0 0 0 0
Equity in Affiliates (Pretax) 0 0 0 0 0
Unusual Expense (1.18M) 2.75M 700,000 0 0
Pretax Income 20.34M 20.71M (4.44M) 9.53M 17.55M
Income Taxes 7.66M 9.04M (1.67M) 1.58M 3.95M
Income Tax - Current - Domestic 684,821 2.9M 4M 1.92M 9.5M
Income Tax - Current - Foreign 0 0 0 - -
Income Tax - Deferred - Domestic 6.98M 6.14M (5.67M) (342,000) (5.55M)
Income Tax - Deferred - Foreign 0 0 0 - -
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income 12.68M 11.67M (2.77M) 7.95M 13.6M
Minority Interest Expense 1.87M 2.81M (257,000) 5.2M 9.97M
Net Income 10.81M 8.86M (2.51M) 2.76M 3.63M
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 - 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries 10.81M 8.86M (2.51M) 2.76M 3.63M
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 10.81M 8.86M (2.51M) 2.76M 3.63M
EPS (Basic) 0.52 0.41 (0.11) 0.12 0.16
Basic Shares Outstanding 20.79M 21.65M 22.12M 22.58M 22.16M
EPS (Diluted) 0.49 0.40 (0.11) 0.12 0.16
Diluted Shares Outstanding 22.14M 22.4M 23.07M 22.91M 23.32M
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
New Milestone for Driven Tech in AI Innovation If there's one thing that's becoming crystal clear in the tech world, it's this: AI isn't just a flashy add-on anymore. Companies are diving deep into AI waters, transforming their business strategies from the ground up. Driven Tech, Inc., is doing just that, and their efforts haven't gone unnoticed—they’ve made it onto...
Continue Reading
A Growing Global Thirst for AI-Enhanced Research It looks like the folks at Clarivate have struck a chord. Their Web of Science Research Intelligence platform is garnering attention across the globe, embraced by more than 100 institutions spanning 25 countries. When you craft something that taps into a core need, well, people will jump on it—and that's exactly what's...
Continue Reading
PKGD Group's Impressive Growth Story Sometimes you read a report and it genuinely knocks the wind out of you—not because it’s unusual, but because it’s rare to see such robust numbers in a market that ain't exactly all sunshine and rainbows. PKGD Group, the brain behind some damn fine agave spirits, decided to take no prisoners this year, reporting a jaw-dropping...
Continue Reading
A Leap in 3D Scanning: Say Hello to M1 Ultra ELEGOO isn't just fiddling with a toy here—this Shenzhen-based juggernaut is rolling out the M1 Ultra on October 29, 2026, and it's causing quite a stir. While the stock market doesn't see immediate tremors from every shiny new gadget, there’s something to say when a company that pulled over $300 million in sales last year...
Continue Reading
RZ-001's European Success: A New Frontier Look, when a biopharmaceutical firm's RNA-editing therapy snags an Orphan Medicinal Product Designation from the European Commission, it's not just some clipboard milestone—it's a heavy-hitter move. That's exactly what Rznomics, the South Korean gene therapy player, pulled off with RZ-001. Now, we aren't just seeing paperwork...
Continue Reading
Edge AI Gets a Rugged Boost with Durabook's R12 In a world teeming with tech gadgets that crumble at the first sign of a challenge, Durabook's R12 Rugged Tablet makes a solid entrance. This ain't your everyday pretty gadget. Think of it as the big, burly bodyguard of tablets, ready to box through harsh environments without dropping a pixel. What’s stirring the pot this...
Continue Reading
Let’s talk about why life insurance isn’t just for those walking around with gray hair. K.D. the Insurance Queen from Centennial, Colorado, dishes out the clearest advice on when and why families ought to have it in their arsenal. A New Mindset on Life Insurance Some folks out there think life insurance is something you ponder in your twilight years. But here’s the...
Continue Reading
Serious Scrutiny for Hims & Hers There's trouble in paradise, folks. Hims & Hers Health, Inc. (NYSE: HIMS) just landed in hot water, and it's not the soothing kind. We're talking about allegations of privacy violations and deceptive practices that have sent ripples—or more like waves—across the investor pond. If you're holding shares, you've probably felt the jolt...
Continue Reading
Breaking Ground in Data Center Power Every so often, the tech industry gets a jolt of innovation that turns heads—not just for what it can do today, but for what it promises tomorrow. This time, it's United Microelectronics Corporation (UMC) and AP Memory shaking things up with their collaboration aimed at redefining power delivery for AI and high-performance computing...
Continue Reading
Not Just Another Day in Tech When tech outfits make headlines, it's often because of a shiny new gadget or some jarring security breach. Today, it's AuraQuantic getting their well-deserved spotlight, having snagged the leader's spot in the SPARK Matrix™ for Intelligent Process Orchestration (IPO). You might be wondering what makes this accolade worth attention in a...
Continue Reading
Top 5 Most Recently Viewed Articles
Analyzing Atlassian's Options Activity Recently, significant activity has been noted in the options market for Atlassian (NASDAQ: TEAM), suggesting fluctuating sentiment among investors. With several key trades occurring, it is vital to understand the underlying forces driving these changes. Insights from Options Trading An examination of options history indicates that a...
Continue Reading
Oncolytics Biotech's Strategic Move to Lead Cancer Innovation In a time where the global oncology drug market is projected to exceed an astounding $900 billion, interest in cancer-focused biotechnology companies has surged significantly. Analysts highlight the increasing demand for innovative diagnostics and advanced immunotherapies driving this growth. Yet, as these...
Continue Reading
Changes in Leadership at Admirals Group AS Admirals Group AS recently held a significant general meeting where key changes to its management and supervisory boards were decided. Effective from a stated future date, Anton Tikhomirov and Fedor Ragin have been appointed to the supervisory board for a term of five years. This shift marks an exciting new chapter in the...
Continue Reading
Athens Stock Market Performance Overview The latest updates reveal that Greece's stock market has closed on a positive note, showcasing notable increases across various sectors. The Athens General Composite Index has gained traction, finishing higher as key market sectors, particularly Construction, Travel, and Banking, experienced substantial growth. Sectorwise...
Continue Reading
Introduction to Tremfya and Crohn's Disease Tremfya, a medication developed by Johnson & Johnson, has gained notable attention for its role in treating Crohn's disease. Recently, new results from its Phase 3 GRAVITI study have sparked interest in its potential expanded usage, showing promising outcomes for patients. Exciting Results from the GRAVITI Study The GRAVITI...
Continue Reading